Abstract
Evidence-based pharmacotherapies are lacking for military-related PTSD. TNX-102 SL* is a proprietary formulation of cyclobenzaprine (CBP) for bedtime sublingual administration that bypasses first pass metabolism and antagonizes 5-HT2A, 1-adrenergic and histaminergic-1 receptors. It is hypothesized to improve PTSD via effects on core symptoms of sleep disturbance and hyperarousal.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
